Maria Carrillo-Marquez, MD, MS: Moderna ( concluded): Site PI. Phase 3 Study to Evaluate the Safety and Immunogenicity of mRNA-1273.214 Vaccine for SARS-CoV-2 Variants in 6 months <6 years; Moderna (concluded): Site PI. Phase 2 Study to Evaluate Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214 Vaccine in 12 weeks to <6 months; Pfizer: Site PI. ClinicalTrials.gov identifier: NCT05639647
